Abstract
Introduction: Surgical resection with curative intent followed by adjuvant chemotherapy is still the standard of care in pancreatic cancer (PC). Neoadjuvant chemotherapy is more and more administered to borderline-resectable (BR) and locally advanced (LA) PC with achievement of higher percentage of resectability and improvement of oncological outcomes. Currently, total neoadjuvant therapy (TNT), intended as induction chemotherapy (IC) followed by radiochemotherapy (RCT), has been taking hold. Aim of this review is to summarize the available evidence on the role of TNT.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
